Skin Cancer Scanning Ltd. (SCS) is a medical device company focused on developing and marketing a non-invasive, painless test that can be completed quickly in the doctor’s office. Our objective is to improve early detection and more accurately diagnose skin cancer and precancerous lesions.

Our early detection device, SkinScan 650, enables physicians to improve their diagnostic abilities using state-of-the-art technology. This replaces current diagnostic procedures that have many disadvantages, such as being relatively subjective and dependent on the experience of the examiner. Errors in diagnosis can be fatal. Cancers can remain undetected, grow further and reduce to chances of survival. A biopsy, the intrusive removal of tissue sample, is usually needed for further diagnoses.

SkinScan 650 provides a clear value proposition, both to the patient and healthcare system:

• Diagnoses cancerous lesions on the spot. Diagnosing cancer at an early stage enables a greater opportunity to cure and lower treatment costs.
• Reduces the number of referrals for biopsies. This has many clear disadvantages:
  • Less scarring: A biopsy can result in cosmetic scarring
  • Less pain: Biopsies require intrusive removal of tissue that can be painful and expensive
  • Less patient anxiety: There is a time lag between the examination and the biopsy results. This increases costs, inconvenience to the patient, and the risk the disease will reach a point where it is harder to treat. In addition, this waiting period causes significant anxiety to the patient.

So far we have successfully completed two stages of clinical trials at the Rabin Medical Center in Petah Tikva, Israel. We plan to soon launch SkinScan 650 commercially in major world markets.

Patents Pending

Patent applicants have been submitted in both the US (Patent pending 11/464,838) and worldwide under the PCT framework (PCT/IL2006/000954).